Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of FBF001 in Healthy Male Subjects
NCT02295813Phase 1Completed
- Sponsor
- Fabentech
- Start
- Oct 2012
- Primary completion
- Dec 2012
- Modality
- Antibody-Based Therapeutics
01
Overview
Phase 1, randomised, double-blind trial in Avian influenza H5N1 (H5N1) comparing FBF001 with Placebo (2 arms). Primary endpoints: Blood pressure, ECG evaluation and 6 more. Started Oct 2012; status: completed.
02
Drugs
FabenFLU
03
Conditions
Avian influenza H5N1 (H5N1)
Beyond the preview
Go deeper on NCT02295813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02295813.